Chad

Reimbursed Care Access

Chad does not have any publicly documented, permissive national framework for therapeutic or reimbursed use of classic psychedelics. Most internationally recognised psychedelic compounds (psilocybin, MDMA, DMT, mescaline, 5‑MeO‑DMT, ibogaine, 2C‑X series, ayahuasca preparations) are effectively prohibited for non‑research use under the international drug control framework and national enforcement practices; ketamine is available as an essential anesthetic in clinical settings but psychedelic/psychiatric uses (and licensed esketamine products) are not reported as reimbursed in Chad. Access for most psychedelics is therefore limited to approved clinical research (where it exists) or is unlawful outside clinical trials or authorised medical uses.